Partial
Partially Aligned
Patient Risk:
Info
Summary
Only the mechanism-of-action statement is directly supported by the provided label excerpt (12.1). Other claims (indications, dosing, side effects, FDA approval date, manufacturer, and efficacy/severity effects) are not supported or verifiable from the supplied text sections.
Category Scores
Accurate Statements
Atogepant belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists.
12.1: "Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist."
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
12.1: "Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist."
QULIPTA is taken orally with or without food.
2.1 Recommended Dosage: "QULIPTA is taken orally with or without food."
Unsupported Statements
Atogepant is approved for the preventive treatment of episodic migraine in adults.
No approved indication text for episodic migraine in adults is included in the supplied label excerpts.
Atogepant works by blocking the action of CGRP.
The provided excerpt (12.1) states it is a CGRP receptor antagonist, but does not explicitly say it blocks the action of CGRP.
By inhibiting CGRP, atogepant is thought to reduce the frequency of migraine attacks.
No clinical efficacy statement regarding reducing frequency is included in the supplied excerpts.
By inhibiting CGRP, atogepant is thought to reduce the severity of migraine attacks.
No clinical efficacy statement regarding reducing severity is included in the supplied excerpts.
Common side effects of atogepant include upper respiratory tract infection.
No adverse reaction/side effect information is included in the supplied excerpts.
Common side effects of atogepant include nausea.
No adverse reaction/side effect information is included in the supplied excerpts.
Common side effects of atogepant include fatigue.
No adverse reaction/side effect information is included in the supplied excerpts.
The U.S. Food and Drug Administration (FDA) approved atogepant in September 2021.
No FDA approval date information is included in the supplied excerpts.
AbbVie Inc. manufactures and markets atogepant.
No manufacturer/marketing information is included in the supplied excerpts.
Contradictions
Important Omissions
For dosing: explicit confirmation that the recommended dosing statements apply specifically to atogepant (vs. referencing QULIPTA) for episodic migraine and/or chronic migraine is not fully established in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
No contraindication/boxed warning/major safety claims were evaluated because the provided excerpts do not include those sections; several efficacy and adverse-effect claims are unsupported, which could mislead but were not shown to contradict the label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Only the CGRP receptor antagonist mechanism statement is directly supported by the supplied label excerpt; other claims (indication, efficacy rationale, adverse effects, and approval/manufacturer details) are not supported by the provided text.
Suggested Improvement
Limit claims to the supplied label excerpts or provide additional label sections (Indications and Usage, Clinical Studies, Adverse Reactions, How Supplied/Manufactured by, Approval History/Highlights) to support the other statements.